Close Menu

NEW YORK – The UK's National Institute for Healthcare Excellence (NICE) on Friday recommended that the National Health Service provide AstraZeneca's olaparib (Lynparza) in combination with Roche's bevacizumab (Avastin) for certain ovarian cancer patients through the Cancer Drugs Fund (CDF).

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.